By Xzencis AB
Subscribe to Supplier
Subscribe to Supplier
Xzencis contributing Translational Safety insights to BTS meeting Liverpool
Mölnlycke, Sweden: – Xzencis founder Dr. Steffen Ernst will present expert safety consultant insights on Translational Safety to the upcoming British Toxicology Society annual meeting in Liverpool UK.
Dr. Ernst will be appearing in association with one of Xzencis most important clients, UK-based drug toxicology specialists ApconiX Ltd., at the three-day BTS Annual Congress commencing April 15 at the Spaces at the Spine conference center in Liverpool.
Collaborative History
Xzencis and ApconiX have been collaborators for several years, with Dr. Ernst and ApconiX co-founder Richard Knight collaborating as co-authors of chapters on Pharmaceutical Toxicology and Translational Safety Medicine as part of the handbook Principles of Translational Science in Medicine: From Bench to Bedside’, now in its third edition.
Dr. Ernst is also a BTS member as a Eurotox Registered Toxicologist.
In his Day Two address to the BTS (April 16: 1230-1300 hrs), Steffen Ernst will highlight ‘Translational Safety – a pharmaceutical R&D strategy with huge potential’.
Translational Safety as opportunity
Dr. Ernst’s presentation will explain how the Translational Safety discipline is far more than a cost center but can be the foundation of better development method, greater process efficiency, and prolonged product life cycles.
His address will stress the role of Translational Safety in clinical and postlaunch product development, where a seamless, uninterrupted, and objective-driven approach can deliver significant moral, therapeutic and commercial gains.
About Xzencis AB
Xzencis provides a wide suite of expert consultancy services focused on Translational Safety Solutions: planning and executing transitions and problem solving along the entire pharmaceutical value chain from pre-clinical target to market launch and beyond.
The company’s strength is based on in-depth subject matter expertise in medicinal regulation, toxicology, clinical Patient Safety (PS) and Pharmacovigilance (PV), business administration, business development and licensing uniquely combined with hands-on business experience. These allow us to assist any life sciences company or organization with safety and regulatory issues, such as strategy development and execution, pre-clinical and clinical challenges, inbound or outbound licensing, building safety value chains, governance, Due Diligence assessments for investors and organizational design of safety departments.
Where extra personnel are required, Xzencis can call on an extensive network of senior, experienced Toxicologists, NCDS sub-discipline experts, Safety Physicians, Safety Scientists and PV Systems experts – all with tested and proven, impeccable track records.
Learn more at: www.xzencis.com
About BTS Annual Congress 2024
The British Toxicology Society (BTS) is a society for all fields of professional toxicologists and those active in the field, dedicated to driving excellence in toxicology and a mission to provide the UK’s principal forum for this science.
The BTS promotes numerous scientific meetings, professional development courses and networking opportunities, of which the most important is its Annual Congress, first staged in 1979.
The 45th BTS Annual Congress will be a three-day event opening April 15, 2024, at the Spaces at the Spine conference center in Liverpool.
The event is organized by the BTS with further information at: https://www.thebts.org/events/bts-annual-congress-2024-spaces-at-the-spine-liverpool/
Resources
Click on Principles of Translational Science in Medicine From Bench to Bedside 3rd Edition for further information.
Click on About ApconiX Ltd. to learn more.
Related Articles
